



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > US Market Report for Remote Hemodynamic Monitoring Systems 2018 - MedCore

---

# US Market Report for Remote Hemodynamic Monitoring Systems 2018 - MedCore

**Publication ID:**

IDR1017061

**Publication Date:**

November 01, 2017

**Pages:**

377

**Publisher:**

iData Research

**Region:**

USA [1]

**\$2,995.00**

Publication License Type \*

Single User License (PDF), \$2,995.00

Site License (PDF), \$4,493.00

Global License (PDF), \$5,990.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



## **Description:**

Heart failure occurs when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Changes in the pressure of blood through the pulmonary artery can be an indicator of heart failure or worsening heart failure. Following changes in blood pressure, heart failure will cause shortness of breath and weight gain. Heart failure is diagnosed by history of symptoms and a physical examination with confirmation echocardiology. Heart failure afflicts 2% of the adult population in developed nations, which increases to 6 to 10% for those above the age of 65. The highest risk of death is generally right after diagnosis, at around 35%.

Remote hemodynamic monitoring devices are implanted into the patient to monitor the blood pressure in the pulmonary artery. The device takes measurements from inside the body and transmits the data to a secure website for clinicians to review. The clinicians are then able to preemptively able to detect heart failure and treat them before symptoms arise.

## **Table Of Contents:**

TABLE OF CONTENTS	I
LIST OF FIGURES	XII
LIST OF CHARTS	XV
EXECUTIVE SUMMARY	1
U.S. CARDIAC SURGERY AND HEART VALVE DEVICE MARKET OVERVIEW	1
COMPETITIVE ANALYSIS	4
MARKET TRENDS	7
MARKET DEVELOPMENTS	11
PROCEDURE NUMBERS	12
PROCEDURE CODES INVESTIGATED	16
MARKETS INCLUDED	17
KEY REPORT UPDATES	19
VERSION HISTORY	20
RESEARCH METHODOLOGY	21
Step 1: Project Initiation & Team Selection	21
Step 2: Prepare Data Systems and Perform Secondary Research	24
Step 3: Preparation for Interviews & Questionnaire Design	26
Step 4: Performing Primary Research	27
Step 5: Research Analysis: Establishing Baseline Estimates	29
Step 6: Market Forecasts and Analysis	30
Step 7: Identify Strategic Opportunities	32
Step 8: Final Review and Market Release	33
Step 9: Customer Feedback and Market Monitoring	34
DISEASE OVERVIEW	35
2.1 BASIC ANATOMY	35
2.1.11 Coronary Artery Disease	37

2.1.12 Myocardial Infarction	37
2.1.13 Angina Pectoris	38
2.1.14 Heart Valve Disease	39
2.1.15 Congestive Heart Failure	39
PRODUCT PORTFOLIO	41
3.1.1 Tissue Heart Valves	41
3.1.2 Mechanical Tissue Heart Valves	43
3.1.3 Annuloplasty Repair Devices	45
3.1.4 Transcatheter Aortic Valve Replacement Devices	47
3.1.5 Transcatheter Mitral Valve Repair Devices	49
3.1.6 On-Pump Coronary Artery Bypass Devices	50
3.1.7 Off-Pump Coronary Artery Bypass Devices	52
3.1.8 Endoscopic Vessel Harvesting Devices	53
3.1.9 Anastomosis Assist Devices	54
3.1.10 Transmyocardial Revascularization Devices	55
3.1.11 Ventricular Assist Devices	56
3.1.12 Intra-Aortic Balloon Pump Device	57
3.1.13 Temporary Artificial Heart Replacement Device	58
3.1.14 Remote Hemodynamic Monitoring System Devices	59
3.1.15 Patent Foramen Ovale Devices	59
3.1.16 Atrial & Ventricular Septal Defect Device	61
3.1.17 Left Atrial Appendage Closure Device	62
3.1.18 Extracorporeal Membrane Oxygenation Machine	63
3.2 FDA RECALLS	64
3.2.1 MAQUET	64
3.2.2 Medtronic	66
3.2.3 HeartWare Inc	67
3.3 CLINICAL TRIALS	68
3.3.1 Medtronic	68
3.3.2 St. Jude Medical	70
3.3.3 Abiomed	75
3.3.4 Heartware Inc	76
REMOTE HEMODYNAMIC MONITORING SYSTEM MARKET	78
4.1 INTRODUCTION	78
4.2 MARKET ANALYSIS AND FORECAST	79
4.3 DRIVERS AND LIMITERS	81
4.3.1 Market Drivers	81
4.3.2 Market Limiters	81
4.4 COMPETITIVE MARKET SHARE ANALYSIS	83
ABBREVIATIONS	85

## APPENDIX: COMPANY PRESS RELEASES 88

### List of Chart

Chart 1 1: Cardiac Surgery and Heart Valve Devices Market by Segment, U.S., 2014 – 2024 3

Chart 1 2: Cardiac Surgery and Heart Valve Devices Market Overview, U.S., 2017 & 2024 3

Chart 4 1: Remote Hemodynamic Monitoring System Market, U.S., 2014 – 2024 80

Chart 4 2: Leading Competitors, Remote Hemodynamic Monitoring System Market, U.S., 2017 84

### List of Figures

Figure 1 1: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (1 of 4) 4

Figure 1 2: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (2 of 4) 5

Figure 1 3: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (3 of 4) 5

Figure 1 4: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (4 of 4) 5

Figure 1 5: Companies Researched in this Report, U.S., 2017 6

Figure 1 6: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (1 of 4) 7

Figure 1 7: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (2 of 4) 8

Figure 1 8: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (3 of 4) 9

Figure 1 9: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (4 of 4) 10

Figure 1 10: Recent Events in the Cardiac Surgery and Heart Valve Devices Market, U.S., 2015 – 2017 11

Figure 1 11: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (1 of 4) 12

Figure 1 12: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (2 of 4) 13

Figure 1 13: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (3 of 4) 14

Figure 1 14: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (4 of 4) 15

Figure 1 15: Procedure Codes Investigated, U.S., 2017 16

Figure 1 16: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (1 of 2) 17

Figure 1 17: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (2 of 2) 18

Figure 1 18: Key Report Updates (1 of 2) 19

Figure 1 19: Key Report Updates (2 of 2) 20

Figure 1 20: Version History 20

Figure 3 1: Tissue Heart Valves by Company 42

Figure 3 2: Mechanical Tissue Heart Valves by Company 44

Figure 3 3: Annuloplasty Repair Devices by Company 46

Figure 3 4: Transcatheter Heart Valve Replacement Devices by Company 48

Figure 3 5: Transcatheter Mitral Valve Repair Devices by Company 49

Figure 3 6: On-Pump Coronary Artery Bypass Devices by Company 51

Figure 3 7: Off-Pump Coronary Artery Bypass Devices by Company 52

Figure 3 8: Endoscopic Vessel Harvesting Devices by Company 53

Figure 3 9: Anastomosis Assist Devices by Company 54

Figure 3 10: Transmyocardial Revascularization Devices by Company 55

Figure 3 11: Ventricular Assist Devices by Company 56

Figure 3 12: Intra-Aortic Balloon Devices by Company 57

Figure 3 13: Temporary Artificial Heart Replacement Devices by Company 58

Figure 3 14: Remote Hemodynamic Monitoring System Devices by Company 59

Figure 3 15: Patent Foramen Ovale Devices by Company 60

Figure 3 16: Atrial & Ventricular Septal Defect Devices by Company 61

Figure 3 17: Left Atrial Appendage Closure Devices by Company 62

Figure 3 18: Extracorporeal Membrane Oxygenation Machine by Company 63

Figure 3 19: Class 2 Device Recall MAQUET 64

Figure 3 20: Class 2 Device Recall MAQUET 64

Figure 3 21: Class 2 Device Recall MAQUET 65

Figure 3 22: Class 1 Device Recall Medtronic 66

Figure 3 23: Class 1 Device Recall Heartware Inc 67

Figure 3 24: The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study 68

Figure 3 25: Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance 68

Figure 3 26: Medtronic CoreValve Evolut R U.S. Clinical Study 69

Figure 3 27: Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients 69

Figure 3 28: AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption 70

Figure 3 29: AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) 70

Figure 3 30: HeartMate 3 CE Mark Study Long Term Follow-up (HM3 CE LTFU) 71

Figure 3 31: Trifecta™ GT Post Market Clinical Follow-up 71

Figure 3 32: AMPLATZER™ LAA Occluder Post Approval Study (PAS) 72

Figure 3 33: AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP PAS China) 72

Figure 3 34: MOMENTUM 3 Continued Access Protocol (MOMENTUM 3 CAP) 73

Figure 3 35: AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE) 73

Figure 3 36: Prevention of Non-Surgical Bleeding by Management of HeartMate II 74

Figure 3 37: Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction (DTU) 75

Figure 3 38: Protected PCI Study 75

Figure 3 39: Assessment of the WATCHMAN™ Device 76

Figure 3 40: Watchman FLX Left Atrial Appendage Closure Device Post Approval Study 76

Figure 3 41: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology 77

Figure 4 1: Remote Hemodynamic Monitoring System Market, U.S., 2014 - 2024 79

Figure 4 2: Drivers and Limiters, Remote Hemodynamic Monitoring System Market, U.S., 2017 82

Figure 4 3: Leading Competitors, Remote Hemodynamic Monitoring System Market, U.S., 2017 83

Figure 6 1: Press Release Summary 88

## **License Types:**

### **Single User License (PDF)**

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

### **Site License (PDF)\***

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

### **Global License (PDF)\***

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in

presentations and internal reports by providing full copyright credit to the publisher.

\*If Applicable.



No. 1101, Golden Square, 3rd Floor,  
24th Main, J P Nagar, 1st Phase,  
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

## NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

## RECENT POSTS

[What is drug pipeline research?](#)

March 20

[How to use market research to bring your idea to life?](#)

March 11

[How to gain business insights using syndicated market research?](#)

March 10

---

Source URL: <https://www.drugpipeline.net/idata-research/us-market-report-remote-hemodynamic-monitoring-systems-2018-medcore>

Links

[1] <https://www.drugpipeline.net/region/usa>